Skip to main content
Revelle Capital

Sector Focus

Private Credit for Healthcare & Life Sciences

Specialist private credit structures for healthcare operators, pharma services businesses, medtech companies, and care providers - financing resilient, regulated revenue streams that traditional banks often struggle to underwrite.

300+Lenders
15+Years Experience
100+Clients Served
10+Jurisdictions Covered

Why Healthcare Businesses Turn to Private Credit

Healthcare and life sciences businesses occupy a distinctive position in the lending landscape. Their revenues are often underpinned by demographic tailwinds, regulatory frameworks, and essential service demand that creates unusual cash flow resilience. Yet traditional banks frequently struggle with the sector because of its complexity: regulatory risk, reimbursement uncertainty, capital expenditure cycles, and the operational intensity of clinical or care delivery environments.

Private credit funds have developed specialist healthcare teams that understand these dynamics. They can underwrite revenue streams that banks find opaque - from NHS-contracted care home income to medtech consumable revenues and pharmaceutical outsourcing contracts. This expertise translates into larger facilities, more flexible structures, and faster execution for healthcare borrowers.

The European healthcare private credit market has expanded rapidly as several structural forces converge. An ageing population across Western Europe is driving sustained demand for care services, diagnostics, and medical devices. Governments are increasingly outsourcing healthcare delivery to private operators, creating contracted revenue streams that private credit lenders value highly. Meanwhile, PE sponsors have identified healthcare as a core sector for buy-and-build strategies, generating a steady pipeline of acquisition financing opportunities.

Three factors make private credit particularly well-suited to healthcare businesses:

  • Revenue resilience. Healthcare demand is largely non-discretionary. Care home occupancy, diagnostic testing volumes, and pharmaceutical consumption are far less cyclical than most other sectors. Private credit lenders recognise this resilience and are willing to provide higher leverage against healthcare cash flows than against more cyclical industries, often sizing facilities 0.5-1.0x higher on an EBITDA-multiple basis.
  • Regulatory complexity as a moat. The regulatory barriers that deter banks from lending into healthcare actually create value for specialist private credit lenders. CQC registration, NHS commissioning frameworks, MHRA device approvals, and GMP compliance all represent barriers to entry that protect incumbent operators. Lenders who understand these frameworks can underwrite with confidence that competitive disruption risk is lower than in unregulated sectors.
  • Buy-and-build opportunity. Healthcare remains highly fragmented across Europe. A typical PE-backed platform in veterinary services, dental care, or specialist diagnostics may execute 10-20 bolt-on acquisitions during a hold period. Private credit structures with delayed-draw term loans and accordion features are purpose-built for this acquisition cadence, providing committed capital without requiring separate financing processes for each transaction.

Typical Deal Structures

Unitranche

Single-tranche facility combining senior and subordinated debt. The dominant structure for PE-backed healthcare platform acquisitions above 40 million enterprise value. Healthcare unitranche facilities often incorporate specific provisions for CQC compliance, regulatory change protections, and NHS contract renewal cycles.

Most common for sponsor-backed deals in care services, diagnostics, and veterinary

Asset-Backed Healthcare Facility

Facilities secured against healthcare-specific assets including freehold property portfolios (care homes, clinics), medical equipment fleets, and long-term NHS or local authority contracts. Asset-backed structures can achieve lower pricing than cash flow-only facilities, particularly where freehold property provides tangible collateral coverage.

Pricing typically 100-200bps tighter than unsecured equivalents

Acquisition Credit Line

Committed revolving or delayed-draw facility specifically earmarked for bolt-on acquisitions in buy-and-build strategies. Healthcare consolidation platforms draw on these facilities to acquire individual practices, clinics, or small operators. Advance rates and terms are pre-agreed for acquisitions meeting defined criteria.

Draw periods of 18-36 months typical for healthcare roll-ups

Capex Facility

Dedicated tranche for capital expenditure on medical equipment, facility refurbishment, or new site development. Healthcare businesses often require significant upfront investment in equipment or facility upgrades to meet regulatory standards or expand capacity. Capex facilities ring-fence this investment from the main operating facility.

Commonly structured alongside unitranche for care home and hospital operators

Mezzanine / Holdco PIK

Subordinated facility providing additional leverage beyond the senior or unitranche layer. Used in healthcare acquisitions where the equity valuation exceeds what senior debt alone can support. Payment-in-kind interest preserves cash flow during integration periods when operational improvements are being implemented.

Priced at EURIBOR + 800-1100bps or fixed 11-14%

Discuss Your Financing Requirements

Our team structures private credit facilities across European markets. Tell us about your transaction and we will identify the right lenders.

Start a Conversation

Key Metrics & Terms

Healthcare private credit terms reflect the sector's combination of revenue stability, regulatory oversight, and capital intensity. The metrics below represent the range observed across European healthcare transactions in the current market.

Leverage
4.5-7.0x Adjusted EBITDA
Higher leverage available for businesses with contracted NHS or government revenues, freehold property, and diversified site portfolios. Single-site operators typically cap at 4.5-5.5x.
Pricing (Unitranche)
EURIBOR + 500-750bps
Healthcare typically achieves tighter pricing than comparable leverage in more cyclical sectors, reflecting the non-discretionary nature of demand. All-in cost including fees typically 7.0-9.5%.
Typical Deal Size
20 million - 250 million
The healthcare market supports a wide range of deal sizes from single-site care home refinancings through to large platform acquisitions. Club deals for larger healthcare platforms above 250 million are increasingly common.
Maturity
5-7 years
Bullet repayment structures dominate for PE-backed transactions. Care home and property-heavy healthcare businesses may see amortisation of 2-5% per annum reflecting the freehold asset base.
Call Protection
NC-1 to NC-2, then 102/101
Standard call protection mirrors broader private credit market practice. Some lenders offer softer call provisions for healthcare borrowers with strong credit profiles.
Covenants
1-2 maintenance covenants or covenant-lite
Healthcare-specific covenant additions may include minimum occupancy rates (care homes), CQC rating maintenance, staff-to-patient ratios, and regulatory compliance certifications. These supplement standard financial covenants.
Equity Contribution
35-50% of enterprise value
Healthcare's defensive characteristics allow slightly lower equity requirements than more cyclical sectors. Operators with freehold property portfolios may achieve more favourable equity splits.
Diligence Timeline
5-8 weeks
Healthcare diligence is typically more involved than other sectors due to regulatory reviews, clinical quality assessments, and reimbursement analysis. Specialist advisors are usually required.

The European Healthcare Lending Landscape

The pool of private credit lenders with genuine healthcare expertise in Europe has grown significantly. Healthcare's combination of defensive revenues and consolidation opportunity has attracted dedicated sector teams across the major lending platforms.

Healthcare-Specialist Credit Funds. Several funds focus exclusively or primarily on healthcare lending, maintaining teams with clinical, regulatory, and operational backgrounds alongside traditional credit analysis. These specialists understand CQC inspection frameworks, NHS commissioning cycles, and pharmaceutical regulatory pathways in ways that generalist lenders cannot replicate. Their competitive advantage lies in speed of diligence and comfort with sector-specific risks.

Large-Cap Direct Lending Platforms. The major European direct lending platforms all maintain dedicated healthcare coverage teams. These platforms can underwrite facilities of 100 million and above for PE-backed healthcare acquisitions and are particularly well-positioned for large platform transactions requiring certainty of financing across multiple jurisdictions.

Real Estate-Healthcare Hybrid Lenders. For healthcare businesses with significant freehold property (care homes, hospitals, clinics), a category of lenders combines real estate lending expertise with healthcare operational understanding. These lenders can offer enhanced leverage and tighter pricing by blending property collateral value with operating cash flow analysis.

Government-Adjacent Lending Programmes. In several European markets, government-backed lending schemes support healthcare infrastructure investment. While not technically private credit, these programmes can form part of a blended capital structure alongside private credit facilities, reducing the overall cost of capital for healthcare operators undertaking facility expansion or modernisation.

The competitive dynamics in healthcare lending have evolved. Lenders increasingly differentiate on sector knowledge and relationship continuity rather than pricing alone. Healthcare borrowers with ongoing acquisition programmes value lenders who can provide rapid approvals for bolt-on transactions within pre-agreed parameters, reducing execution risk on time-sensitive deals.

Deal Reference: UK Care Home Platform Refinancing and Expansion

Anonymised reference based on comparable transactions seen on the market.

SectorElderly Care Services
Deal Size95 million unitranche + 30 million DDTL + 15 million capex facility
Leverage5.8x Adjusted EBITDA at closing. DDTL sized to accommodate 4-6 bolt-on acquisitions within existing leverage parameters. Capex facility structured with 18-month draw period and 5-year amortising repayment.
Tenor6-year maturity on unitranche, bullet repayment. NC-2, then 102/101 soft call. DDTL availability of 24 months. Capex facility amortising from month 18.
StructureUnitranche term loan secured against a portfolio of 22 freehold care homes, supplemented by a delayed-draw facility for acquisitions and a ring-fenced capex line for facility refurbishment. Covenant package included minimum portfolio occupancy of 82% and maintenance of CQC Good or Outstanding ratings across 90% of sites.
OutcomeA specialist healthcare PE fund refinanced an existing bank facility that had become restrictive as the platform grew beyond the bank's single-borrower exposure limits. The private credit unitranche provided 35 million of additional capacity over the bank facility, while the DDTL gave committed financing for pipeline acquisitions. Within 18 months, three bolt-on care homes were acquired using the DDTL, expanding the portfolio to 25 sites and growing EBITDA by 28%. The capex facility funded refurbishment of four older homes, improving their CQC ratings and enabling higher fee rates.

Tell Us About Your Transaction

Share your deal parameters and our team will map the lender landscape. Confidential, no-obligation.

1
Deal Overview
2
Company Profile
3
Contact Details
Confidential
24 Hour Response
No Obligation

Related Private Credit Pages

Explore more private credit topics

Sector

Private Credit for Manufacturing & Industrials

How private credit supports capital-intensive manufacturing businesses with asset-backed and cash flow lending structures.

Country

Private Credit in the United Kingdom

Overview of the UK private credit market, the largest in Europe, including regulatory environment and active lenders.

Transaction

Acquisition Financing

How private credit structures support M&A transactions, including unitranche, term loans, and delayed-draw facilities for buy-and-build strategies.

Comparison

Private Credit vs Bank Lending

Side-by-side comparison of private credit and traditional bank lending across pricing, speed, flexibility, and covenant structures.

Guide

What Is Private Credit?

Foundational guide to private credit markets, covering how direct lending works, who participates, and what borrowers should expect.

Frequently Asked Questions

Common questions about private credit for this sector

Private credit lenders with healthcare expertise assess care home businesses across several dimensions that go beyond standard financial analysis. Occupancy rates and trends are evaluated at both portfolio and individual site level, with stabilised occupancy above 85% generally required for full leverage. Fee composition is analysed to understand the split between local authority-funded and private-pay residents, as private-pay revenues are viewed more favourably due to higher margins and less regulatory risk. CQC ratings are scrutinised closely - a portfolio with predominantly Good or Outstanding ratings will achieve materially better terms than one with Requires Improvement sites. Staff ratios, agency usage, and wage cost trends are examined to assess operational sustainability. Freehold versus leasehold tenure significantly impacts available leverage, with freehold portfolios supporting 1.0-1.5x higher leverage. Lenders also consider geographic concentration, local authority payment reliability, and the regulatory pipeline for new care home supply in the operator's markets.
Healthcare leverage multiples in European private credit typically range from 4.5x to 7.0x Adjusted EBITDA, depending on sub-sector, revenue quality, and asset backing. Care home operators with diversified freehold portfolios and strong CQC ratings can achieve 5.5-7.0x. Pharma services businesses with contracted revenues from large pharmaceutical companies typically see 5.0-6.5x. Medtech distributors with recurring consumable revenues achieve 4.5-6.0x. Veterinary and dental consolidation platforms, which benefit from fragmented markets and predictable demand, regularly access 5.5-6.5x. The key adjustments that lenders scrutinise in healthcare EBITDA include add-backs for acquisition integration costs, run-rate adjustments for recently acquired sites, and normalisation of temporary staffing costs. Lenders with genuine sector expertise will differentiate between sustainable operational improvements and aggressive financial engineering.
Yes, and in many cases NHS contract exposure is viewed positively by private credit lenders. NHS-commissioned revenues represent government-backed cash flows with low credit risk and predictable payment cycles. Lenders value the visibility that multi-year NHS contracts provide, and some specialist healthcare lenders will extend additional leverage against contracted NHS revenue streams. However, lenders also assess the risks specific to NHS exposure: tariff changes, commissioning restructuring, and the potential for contract retendering. Businesses with high NHS concentration (above 70-80% of revenue) may face questions about margin sustainability if tariff rates are reduced. The most favourably viewed structures combine NHS-contracted base revenue with a growing private-pay component, providing both stability and margin expansion potential. Lenders expect borrowers to maintain strong clinical outcomes data and patient satisfaction metrics, as these are increasingly tied to NHS contract renewal and tariff levels.
Medtech and medical device companies access private credit through structures tailored to their specific revenue model. Companies with installed base consumable models - where an initial device placement generates recurring consumable or service revenue - are underwritten similarly to software businesses, with lenders sizing facilities against the recurring revenue component. Leverage of 4.0-6.0x EBITDA is typical for established medtech businesses with proven products and regulatory approvals. The key diligence areas for medtech lending include the regulatory status of products across target markets (CE marking, MHRA approval), reimbursement pathways and any pending tariff changes, customer concentration among hospital groups or distributors, and product lifecycle risk. Companies still in the product development or clinical trial phase are generally not suitable for private credit and should seek venture debt or equity capital instead. For PE-backed medtech platforms executing consolidation strategies, private credit provides acquisition financing with committed facilities for pipeline targets.
Healthcare private credit diligence is more extensive than most sectors, typically requiring 5-8 weeks and involving specialist advisors alongside standard financial and legal workstreams. Regulatory diligence is paramount: lenders will review CQC inspection histories, MHRA compliance records, or equivalent regulatory status across all operating jurisdictions. Clinical quality metrics including patient outcomes, incident rates, safeguarding records, and complaints data are evaluated. Workforce analysis covers staff-to-patient ratios, vacancy rates, agency dependency, and wage benchmarking against sector norms. For care homes, individual site inspections may be required. Revenue diligence examines contract terms, tariff structures, occupancy trends, and fee rate analysis by payer type. Property diligence for freehold sites includes condition surveys, environmental assessments, and fire safety compliance. Lenders increasingly request ESG assessments covering clinical governance, staff wellbeing, and environmental sustainability of facilities. Having a comprehensive data room prepared in advance, including regulatory correspondence, clinical audit reports, and workforce analytics, can significantly accelerate the process.
Yes, healthcare private credit facilities typically include sector-specific covenants alongside standard financial maintenance tests. Common healthcare covenants include minimum occupancy levels (for care home and hospital operators, typically set at 80-85% of stabilised occupancy), maintenance of regulatory ratings (requiring a specified percentage of sites to hold Good or Outstanding CQC ratings), minimum staffing ratios tied to registered manager and qualified nurse requirements, and insurance coverage maintenance for clinical negligence and employer liability. Some facilities include reporting covenants requiring quarterly disclosure of clinical quality metrics, regulatory inspection results, and workforce data. Financial covenants typically include net leverage and fixed charge coverage ratios, with healthcare businesses sometimes benefiting from wider covenant headroom (30-40%) reflecting the stability of their revenue streams. Breach of regulatory covenants is usually treated as an event of default, reflecting the existential risk that loss of regulatory approval poses to a healthcare operator.

Let Us Find the Right Private Credit Solution

With access to 300+ lenders across Europe, we match borrowers with the capital structures that fit. Confidential, no-obligation initial conversation.